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Abstract IFIT (interferon-induced with tetratricopeptide repeats) proteins are critical mediators
of mammalian innate antiviral immunity. Mouse IFIT1 selectively inhibits viruses that lack 2’O-
methylation of their mRNA 5’ caps. Surprisingly, human IFIT1 does not share this antiviral
specificity. Here, we resolve this discrepancy by demonstrating that human and mouse IFIT1 have
evolved distinct functions using a combination of evolutionary, genetic and virological analyses.
First, we show that human IFIT1 and mouse IFIT1 (renamed IFIT1B) are not orthologs, but are
paralogs that diverged >100 mya. Second, using a yeast genetic assay, we show that IFIT1 and
IFIT1B proteins differ in their ability to be suppressed by a cap 2’O-methyltransferase. Finally, we
demonstrate that IFIT1 and IFIT1B have divergent antiviral specificities, including the discovery that
only IFIT1 proteins inhibit a virus encoding a cap 2’O-methyltransferase. These functional data,
combined with widespread turnover of mammalian IFIT genes, reveal dramatic species-specific
differences in IFIT-mediated antiviral repertoires.
DOI: 10.7554/eLife.14228.001
Introduction
Mammalian antiviral defenses rely on the combined functions of a vast collection of immunity genes.
One important arm of the immune system is innate, or cell intrinsic, antiviral immunity, which estab-
lishes an antiviral state in cells by signaling through the cytokine interferon (IFN) and subsequent
upregulation of hundreds of genes known collectively as IFN-stimulated genes (ISGs). ISGs serve as
the first line of defense against viruses and typically function to sense pathogen-associated molecular
patterns (PAMPs) or directly restrict virus replication (Schneider et al., 2014; Schoggins, 2014).
Among the most highly upregulated ISGs are members of the IFIT (interferon-induced with tetra-
tricopeptide repeats) genes. Upon IFN-stimulation or viral infection, the mRNA levels of IFITs
increase 100- to 1000-fold, and IFIT proteins have been implicated in inhibition of a broad range of
viruses (Diamond and Farzan, 2013; Fensterl and Sen, 2015; Vladimer et al., 2014). However, the
number and identity of IFIT genes can vary substantially between species. For instance, while
humans have five intact IFIT genes (IFIT1, 1B, 2, 3 and 5), rats have four (IFIT1, 1b, 2 and 3) and mice
have six (IFIT1, 1b, 1c, 2, 3 and 3b) (Fensterl and Sen, 2011; 2015; Liu et al., 2013). The functional
consequences of IFIT family evolution are unknown, in part because the antiviral functions and spe-
cificities of IFITs are incompletely characterized. Initial studies with IFIT1 and IFIT2 from humans and
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mice indicated that these proteins might mediate their antiviral activity by inhibiting mRNA transla-
tion through interactions with the translation initiation factor eIF3 (Guo et al., 2000; Hui et al.,
2003; Terenzi et al., 2005). In this way, IFITs appeared to function similarly to another critical medi-
ator of the innate immune system, Protein Kinase R (PKR), by globally inhibiting mRNA translation. In
the case of PKR, the recognition of cytoplasmic double-stranded RNA, a by-product of viral replica-
tion, triggers its activity and the global repression of protein synthesis (Dever et al., 2007). Such a
’self versus non-self’ molecular pattern has been more enigmatic for IFIT proteins, and it has been
challenging to determine how IFITs discriminate viral from host RNAs to repress viral replication
specifically.
An elegant means by which one IFIT protein distinguishes ’self versus non-self’ mRNAs was
revealed by recent studies on mouse IFIT1. During mammalian mRNA processing, the 5’ cap region
is 2’O-methylated from a cap0-structure (7mGpppN, where 7mG is the 7-methyl guanosine, ppp is
the triphosphate linkage, and N is any nucleotide) to a cap1-structure (7mGpppNm) (Bane-
rjee, 1980). This reaction is catalyzed in the host nucleus by a dedicated 2’O-methyltransferase,
known as a cap1-methyltransferase (hCMTR1 in humans) (Belanger et al., 2010). Interestingly, many
viruses have evolved ways to mimic host cap1-structures (Banerjee, 1980; Decroly et al., 2012). For
several viruses that replicate in the cytoplasm, such as poxviruses, flaviviruses, coronaviruses, and
rhabdoviruses, 2’O-methylation of the cap is catalyzed by a virally-encoded cap1-methyltransferase.
For other viruses, such as orthomyxoviruses, arenaviruses, and bunyaviruses, the effect is achieved
by ‘cap-snatching’, in which a segment of cap1-modified host mRNA is appended to viral mRNAs.
Either strategy results in methylated (cap1-) mRNAs, suggesting that unmethylated (cap0-) mRNAs
could be recognized as a ’non-self’ pattern that elicits host immunity. Indeed, mouse IFIT1 was dis-
covered to inhibit replication of numerous viruses naturally lacking or mutated to lack 2’O-methyla-
tion by directly binding and inhibiting translation of cap0-mRNAs (Daffis et al., 2010; Hyde et al.,
2014; Ma et al., 2014; Menachery et al., 2014; Szretter et al., 2012; Zust et al., 2011;
Habjan et al., 2013; Kimura et al., 2013; Kumar et al., 2014). In this way, mouse IFIT1 selectively
eLife digest When a virus is detected in the body, hundreds of different proteins in the immune
system are rapidly produced as a first line of defense to limit the ability of the virus to multiply and
spread. Many of these ‘innate’ immunity proteins have rapidly evolved in mammals in escalating
molecular ’arms races’ with the viruses they target. This makes it more difficult to work out exactly
what job each protein performs. Even when the role of a specific protein has been determined in
mice, for example, it does not always follow that the human protein with the same name will
perform the same role.
The IFIT1 proteins are some of the most highly produced innate immunity proteins in mammals
during viral infections. In the infected cell, host and viral proteins are both made from templates
made of molecules of ribonucleic acid (RNA). Previous work showed that the IFIT1 protein in mice is
able to exploit a critical chemical difference between host and virus RNA to selectively block the
production of virus proteins. However, other research suggests that the human IFIT1 protein does
not use the same chemical difference to distinguish between host and virus RNA.
Here, Daugherty et al. unravel the complicated evolutionary history of IFIT1 proteins to show that
the mouse and human proteins are not as closely related to each other as first thought. Instead, they
belong to two different protein families with distinct roles in fighting viruses. Further experiments
show that the human and mouse IFIT proteins likely discriminate between host and viral RNA using
different cues, leading to their action against different sets of viruses.
Daugherty et al.’s findings highlight that there are additional undiscovered chemical differences
between host and viral RNA that the immune system can exploit to selectively target and stop
viruses from multiplying. Furthermore, these findings re-emphasize the often-overlooked differences
between the immune systems of mice and humans. The finding that mammals have such a diverse
set of IFIT1 immunity proteins may directly explain why different species are susceptible to different
viruses.
DOI: 10.7554/eLife.14228.002
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inhibits viruses that translate proteins from ’non-self’ cap0-mRNAs, while the host protects itself via
’self’ cap1-structures on its mRNAs (Diamond, 2014; Hyde and Diamond, 2015).
Given the importance of the cap0-mRNA versus cap1-mRNA specificity in directing mouse IFIT1’s
repressive effects against viruses, we might expect that other mammalian IFIT1 genes would pre-
serve such discrimination. Surprisingly, studies on human IFIT1 have belied this expectation. For
instance, human IFIT1 was shown to inhibit mRNA translation and replication of parainfluenza virus 5
(PIV5), despite the fact that PIV5 encodes a cap1-methyltransferase and PIV5 mRNAs are 2’O-meth-
ylated on their caps (Andrejeva et al., 2013). Other studies have implicated human IFIT1 in inhibi-
tion of hepatitis C virus (HCV) (Raychoudhuri et al., 2011; Wang et al., 2003), human
papillomavirus (HPV) (Terenzi et al., 2008), influenza A virus (IAV) and vesicular stomatitis virus (VSV)
(Pichlmair et al., 2011), none of which are predicted to translate proteins from cap0-mRNAs.
These seemingly contradictory results regarding the antiviral specificities of mouse IFIT1 and
human IFIT1 have led to a conundrum in the field regarding the molecular functions and antiviral
specificity of IFIT proteins in general. However, one implicit assumption underlying the expectation
that human and mouse IFIT1 should function similarly is that mouse and human IFIT1 represent
orthologous genes. Here, we show that this is not the case. Using detailed phylogenetic analyses of
IFIT genes in vertebrates, made possible by deconvolving the confounding effects of recurrent gene
conversion, we show that human IFIT1 and mouse IFIT1 are two distinct paralogous genes that
diverged early in mammalian evolution. Mouse genomes only have representatives of one of these
paralogous genes (which we rename IFIT1B), whereas several primates have lost IFITB but retained
IFIT1. We further show that these two divergent IFIT1 paralogs have distinct specificities. Using a
genetic assay we developed in budding yeast (which exploits yeast’s inherent lack of a cap1-methyl-
transferase), we show that mouse and other IFIT1B proteins, but not IFIT1 proteins, discriminate
cap0- from cap1-mRNA methylation by selectively inhibiting growth only when a cap1-methyltrans-
ferase is missing. Consistent with this activity, we show that only IFIT1B proteins can inhibit replica-
tion of a virus that lacks functional cap1-methylation. In contrast, we find that human and other IFIT1
proteins can inhibit the growth of yeast or of a virus that encodes a cap1-methyltransferase. Our
findings thus resolve the apparent mystery of IFIT1’s altered antiviral discrimination mechanism in
mouse and human and delineate an important role for human IFIT1 in restriction of viruses including
those that produce cap1-mRNAs. Our analyses also reveal a high degree of dynamism and alternate
retention of IFIT1 or IFIT1B paralogs in mammalian genomes. This IFIT gene turnover might pro-
foundly impact the spectrum of viruses that different mammalian species are capable of restricting.
Results
Mouse IFIT1 and Human IFIT1 are not orthologous but belong to
distinct gene families
The expectation that mouse and human IFIT1 should have a similar antiviral function and specificity
implicitly assumes that these two genes are orthologous, i.e., they diverged when the common
ancestors of humans and mice diverged as species. However, there is evidence suggesting that this
assumption may not be valid. First, there have been extensive changes to the number and identity
of IFIT genes between humans and mice ([Fensterl and Sen, 2011;2015; Liu et al., 2013] and
Figure 1A). Furthermore, mouse IFIT1 is more similar at the sequence level to another human IFIT,
the poorly characterized human IFIT1B, than to human IFIT1 (57% versus 53% pairwise amino acid
identity). Based on these data, and the contradictory functional data for mouse IFIT1 and human
IFIT1 antiviral activities (Andrejeva et al., 2013; Daffis et al., 2010; Pichlmair et al., 2011;
Pinto et al., 2015), we formally tested for IFIT1 orthology between mouse and human. To do so, we
first undertook detailed phylogenetic analyses of the IFIT genes found in several well-assembled
mammalian genomes (Figure 1A).
Our phylogenetic analyses were facilitated by the fact that IFIT genes are located in a single locus
in most mammalian species (Liu et al., 2013). For example, human chromosome 10 contains a single
locus that encodes all five intact IFIT genes: IFIT1, IFIT1B, IFIT2, IFIT3 and IFIT5 (Figure 1A). We
found the IFIT locus organization is similar in many other mammalian genomes including African
green monkeys, rabbits, cats, ferrets, and armadillos (Figure 1A). In this shared syntenic arrange-
ment, two IFIT1 paralogs are found next to each other in the same sense orientation as IFIT2 and
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Figure 1. Discordant signatures of synteny and phylogeny for mammalian IFIT genes. (A) Alignment of the IFIT gene locus from several mammalian
genomes. Colored arrows indicate intact IFIT genes and grey arrows indicate neighboring syntenic genes. At left is a schematic phylogenetic tree
showing the relatedness of the indicated species. In carnivores such as cats and ferrets, the IFIT locus is split with IFIT5 in one chromosomal location
and the remainder of the IFITs in another. In the marmoset genome, the IFIT1B gene has been pseudogenized by frameshift and nonsense mutations,
as indicated by the dashed white arrow. Note that the nomenclature for the IFIT genes marked with asterisks is as previously proposed; we suggest a
revised nomenclature scheme for those genes in this report from Figure 2 onwards. A version of this figure, with revised gene names and coloring, is
found in Figure 2—figure supplement 4. (B) Maximum likelihood phylogenetic tree generated using an alignment of the entire gene sequence of the
indicated IFITs. Bootstrap values greater than 80% are shown along the supported branch. Gene names with asterisks next to them have been revised
from Figure 2 onward. Accession numbers for all sequences are found in Supplementary file 1.
DOI: 10.7554/eLife.14228.003
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IFIT3, suggesting that a single duplication of IFIT1 may have occurred early in mammalian evolution,
i.e., before the radiation of placental mammals over 100 million years ago. In primates, rabbits and
carnivores, the paralogs immediately adjacent to IFIT3 are named IFIT1B in sequence databases,
whereas the distal paralogs are named IFIT1. Based on this previous nomenclature, we will hence-
forth refer to these as the IFIT1 and IFIT1B gene families.
In contrast, the IFIT locus in mice and rats is arranged quite differently than other mammalian
genomes. Instead of two paralogs, mice have three IFIT1 paralogs, two of which are in the opposite
orientation to IFIT2 and IFIT3 (Figure 1A). Thus, shared synteny analyses are not suitable for assign-
ing orthology/ paralogy relationships for the mouse IFIT1 genes. We, therefore, constructed maxi-
mum likelihood phylogenetic trees of full-length IFIT gene sequences across these divergent
mammalian species to determine how mouse IFIT1 genes are related to those found in other species
(Figure 1B). We found unambiguous phylogenetic signatures that delineate IFIT2, IFIT3 and IFIT5
genes into distinct, monophyletic clades that diverged as expected based on known mammalian
species evolution (O’Leary et al., 2013). In contrast to these three gene families, we were unable to
resolve IFIT1 and IFIT1B genes into distinct clades in our phylogenetic analyses. Instead, similar to
previous studies (Liu, 2013), we found several instances of IFIT1 and IFIT1B from the same species
(e.g., cat) appearing more phylogenetically related to each other than to their similarly named genes
from a sister species (e.g., ferret) (Figure 1B).
The discordant phylogenetic signatures of IFIT1 and IFIT1B evolution could have two alternative
explanations. The first is that species-specific duplication may have independently given rise to IFIT1
and IFIT1B genes in different genomes, as has been previously proposed (Liu et al., 2013). Such a
duplication pattern might explain why cat IFIT1B is more phylogenetically related to cat IFIT1 than
to IFIT1B genes from other genomes. However, such an explanation would require recurrent duplica-
tion of IFIT genes in many lineages into the same genetic location and orientation, and is thus
unlikely.
We, therefore, considered an alternate explanation. In this alternative, IFIT1 and IFIT1B genes
duplicated early in mammalian evolution but have recurrently recombined with each other. Resulting
gene conversion would scramble the phylogenetic relatedness of the two genes without altering
their genomic locations. Such gene conversion has been shown to contribute to the evolution of sev-
eral multigene families including mammalian interferon alpha genes (Benovoy and Drouin, 2009;
Hurles, 2004; Petronella and Drouin, 2011; Santoyo and Romero, 2005; Song et al., 2011;
Woelk et al., 2007; Yasukochi and Satta, 2015). To address this possibility, we compared the
sequences of IFIT1 and IFIT1B genes within species and between species to look for evidence of
gene conversion. We found strong characteristic signatures of gene conversion frequently occurring
between the 5’ portions of IFIT1 and IFIT1B genes. For example, the sequences of IFIT1 and IFIT1B
genes in cats are 86% identical at the whole gene level. However, these two genes are 97% identical
in the 5’ ends of the genes (nucleotides 1–948 in cat IFIT1) but only 63% identical in the 3’ ends of
the genes (Figure 2A). This dichotomy is apparent even if we restrict the analysis to just synonymous
substitutions, where we observe a much higher rate of synonymous substitutions in the 3’ region of
the alignment (Figure 2—figure supplement 1). Such an uneven distribution of sequence differen-
ces strongly suggests that the 5’ ends of IFIT1 and IFIT1B underwent gene conversion recently in the
evolution of the cat IFIT locus, leading to sequence homogenization of the first two-thirds of the
gene. In contrast, comparing orthologous genes between species (e.g. IFIT1B between cat and fer-
ret) reveals an even distribution of differences across the gene sequences (Figure 2B) indicating that
both the 5’ and 3’ regions have diverged to the expected degree between species. Moreover, this
pattern of gene conversion is seen in pairwise alignments of many IFIT1 and IFIT1B genes. For
instance, between ferret IFIT1 and IFIT1B, the 5’ ends are 98% identical, but 3’ ends are only 62%
identical (Figure 2B). A similar dichotomy is evident in a comparison between rabbit IFIT1 and
IFIT1B and between armadillo IFIT1 and IFIT1B (Figure 2—figure supplement 1). Interestingly, all of
these gene conversion events have a similar recurrent breakpoint approximately two-thirds of the
way through the gene sequence (Figure 2—figure supplement 1) that maps to a ’pivot’ point
between subdomains in the homologous IFIT5 structure (Abbas et al., 2013) (Figure 2—figure sup-
plement 2). In all cases, the 5’ ends of the IFIT1 genes are largely homogenized, whereas the 3’
ends appear to be consistently diverging. Thus, our findings suggest that recurrent gene conversion
has confounded the phylogenetic relationships of the 5’ segment of IFIT1 and IFIT1B, which likely do
not accurately represent the actual ancestry of these genes.
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Figure 2. An ancient gene duplication gave rise to paralogous IFIT1 and IFIT1B gene families. (A) Comparison of
the nucleotide sequence of cat IFIT1 and IFIT1B indicating gene conversion between the two paralogs. The
middle rectangle represents a pairwise sequence alignment, with black vertical lines indicating differences
between the two gene sequences. Percent nucleotide identity for the whole gene comparison is shown above the
alignment schematic, with the 5’ end and 3’ end percent identities shown below. (B) Additional pairwise sequence
alignments are shown as in part A. Additional examples supporting a common recombination breakpoint are
shown in Figure 2—figure supplement 1. Mapping of the recombination breakpoint onto IFIT structural models
(Abbas et al., 2013; Yang et al., 2012) is shown in Figure 2—figure supplement 2. (C) Maximum likelihood
phylogenetic tree of IFIT genes using only the 3’ end of the gene alignment (corresponding to bases 907–1437 of
human IFIT1). Bootstrap values greater than 80% are shown along the supported branch. For clarity, IFIT2, IFIT3
and IFIT5 branches are collapsed and represented as triangles. A maximum likelihood phylogenetic tree of the 5’
Figure 2 continued on next page
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To determine the phylogenetic relationship of IFIT1 and IFIT1B genes in the absence of gene con-
version, we created a maximum likelihood phylogenetic tree of the same IFIT sequences shown in
Figure 1B, but with just the nucleotide sequences 3’ of the observed recombination breakpoint(s)
(Figure 2C). In contrast to the analyses using the full-length IFIT genes (Figure 1B) or the 5’ end of
the IFIT genes (Figure 2—figure supplement 3), we now discern clear separation of IFIT1 and IFIT1B
genes. Both IFIT1 and IFIT1B genes form distinct monophyletic clades that diverge according to
mammalian species evolution, similar to other IFIT genes. Based on this phylogenetic concordance,
as well as the agreement with synteny data, we infer that this phylogeny reflects the actual ancestry
of IFIT1 and IFIT1B genes in mammals. Importantly, these data indicate that IFIT1 and IFIT1B dupli-
cated early in mammalian evolution. Following this duplication, the 3’ ends of the two genes have
been diverging according to speciation events, whereas the 5’ ends have recurrently recombined.
These data also reveal that all three mouse IFIT1 paralogs (previously named mouse IFIT1, IFIT1b
and IFIT1c) and both rat paralogs (previously named rat IFIT1 and IFIT1b) unambiguously group
within the IFIT1B gene family. We, therefore, infer that mouse and rat have lost all copies of IFIT1,
likely through a deletion of both IFIT1 and the neighboring IFIT5. Instead, mouse and rat genomes
now bear recently duplicated copies of IFIT1B. As a result of our phylogenetic analyses, we hence-
forth refer to these genes as mouse/rat IFIT1B (previously mouse/rat IFIT1), IFIT1B2 (previously
mouse/rat IFIT1b) and IFIT1B3 (previously mouse IFIT1c) (Figure 2C and Figure 2—figure supple-
ment 4). This recombination-aware phylogenetic approach thus reveals substantial changes in the
IFIT gene repertoire even within this limited number of mammalian species.
Duplication, loss and gene conversion repeatedly altered mammalian
IFIT gene repertoires
To determine the broader impact of IFIT gene duplication, loss and conversion beyond our initial
sampling of mammalian species, we assembled over 200 IFIT genes from 51 vertebrate species and
conducted maximum likelihood phylogenetic analyses (Figure 3—figure supplement 1). We found
that most placental mammals contain members of the IFIT1, 1B, 2, 3 and 5 gene families (Figure 3).
In contrast, marsupials encode a more limited set of IFIT genes including a single gene that predates
the IFIT2/IFIT3 duplication and a single gene that predates IFIT1/IFIT1B divergence (Figure 3 and
Figure 3—figure supplement 1). Consistent with other analyses (Liu et al., 2013; Varela et al.,
2014), we also observed independent duplication of IFIT genes in fish, as well as in birds and monot-
remes (Figure 3 and Figure 3—figure supplement 1). Based on these analyses, we infer that the
human-like IFIT repertoire (IFIT1, 1B, 2, 3 and 5) was established when placental mammals diverged
from non-placental mammals approximately 100–200 mya while other vertebrates have undergone
lineage-specific expansions of IFITs.
Consistent with our smaller sample, we found that IFIT1 and IFIT1B could not be resolved using
the whole gene sequence, whereas IFIT2, IFIT3 and IFIT5 could be easily separated into distinct
monophyletic lineages. To formally test for recombination breakpoints between IFIT1 and IFIT1B, we
analyzed the complete set of full-length IFIT genes with GARD and SBP (Kosakovsky Pond et al.,
Figure 2 continued
end of the IFIT gene alignment is shown in Figure 2—figure supplement 3. A figure showing revised gene names
on the gene locus alignment is shown in Figure 2—figure supplement 4.
DOI: 10.7554/eLife.14228.004
The following figure supplements are available for figure 2:
Figure supplement 1. Recurrent gene conversion across several diverse mammalian species has utilized a similar
recombination breakpoint.
DOI: 10.7554/eLife.14228.005
Figure supplement 2. Gene conversion of IFIT1 and IFIT1B homogenizes some IFIT structural domains while
leaving others to independently evolve.
DOI: 10.7554/eLife.14228.006
Figure supplement 3. Phylogenetic tree of the recombining region of mammalian IFIT genes.
DOI: 10.7554/eLife.14228.007
Figure supplement 4. Synteny of mammalian IFITs with updated IFIT1 and IFIT1B gene names.
DOI: 10.7554/eLife.14228.008
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Figure 3. Widespread gene birth, gene loss and gene conversion in vertebrate IFIT genes. Summary table of the IFIT gene repertoire of 51 vertebrate
species (see complete phylogeny in Figure 3—figure supplement 1 as well as expanded regions of trees built from the 5’ and 3’ end of the IFIT gene
alignment in Figure 3—figure supplements 2 and 3). Colored boxes indicate the presence of a given IFIT gene sequence, with multiple copies
indicated as a number to the right of the colored box. Lightened boxes indicate that only a partial or pseudogenized copy of the gene can be found in
the genome. On the phylogenetic tree to the left, X’s indicate deletion or pseudogenization of either IFIT1 or IFIT1B genes from that lineage (see
Figure 3—figure supplement 4 for primate examples). Also shown are predicted occurrences of gene conversion (red-around-blue circles) between
IFIT1 and IFIT1B sequences based on discordance between phylogenetic trees generated from 3’ or 5’ regions of the genes (for carnivore examples
see Figure 3—figure supplement 2). Accession numbers for all sequences are found in Supplementary file 1.
DOI: 10.7554/eLife.14228.009
The following figure supplements are available for figure 3:
Figure 3 continued on next page
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2006), two tools that determine whether there is discordance between phylogenetic trees built from
different regions of an alignment. Both analyses found strong statistical support (GARD p-value
<0.001, SBP 100% model averaged support) for a recombination breakpoint approximately two-
thirds of the way through the IFIT gene sequence (Figure 3—figure supplement 2). Importantly,
performing the same analyses for the 3’ region of the IFIT alignment found no evidence for addi-
tional recombination breakpoints (GARD p-value >0.1, SBP 0% model averaged support), support-
ing the assertion that these regions have not recombined during mammalian IFIT evolution. Indeed,
construction of a phylogenetic tree of this non-recombining region of vertebrate IFITs shows that
IFIT1 and IFIT1B genes cluster into distinct monophyletic clades (Figure 3—figure supplement 2
and supplement 3). In contrast, a phylogenetic tree created from just the 5’ end of vertebrate IFITs
reveals numerous instances of gene conversion, including at least five separate cases in the carni-
vores alone (Figure 3—figure supplement 2).
With this enhanced ability to assign IFIT genes to distinct IFIT1 or IFIT1B families after separating
the confounding effects of gene conversion, we were able to detect lineage-specific duplication and
loss events. For instance, in primates, we found that IFIT1 and IFIT1B genes have diverged as
expected based on primate phylogeny and that all primates encode an intact IFIT1. In contrast, we
found that IFIT1B has been pseudogenized at least twice in the primate lineage as the result of the
introduction of nonsense codons and frameshift mutations, once in chimpanzees and again in both
sequenced New World monkeys (Figure 3—figure supplement 3 and supplement 4). Extending our
surveys across all 51 sampled vertebrate species, we found numerous instances of IFIT gene birth,
gene loss and gene recombination (Figure 3). In total, we found evidence for at least seven indepen-
dent instances of IFIT1B loss, two separate instances of IFIT1 loss, and at least 13 independent
instances of IFIT1/1B gene conversion. Interestingly, it appears that most changes in the gene reper-
toire of IFITs across mammalian species are focused on IFIT1 and IFIT1B, although there are also
instances of lineage-specific gene births and loss in other IFIT genes as well. For example, IFIT3 has
duplicated in mice, whereas IFIT5 has been lost in several rodents (which may have occurred coinci-
dent with IFIT1 loss). These changes have led to a significant evolutionary turnover in the IFIT gene
repertoire of different mammalian lineages, prompting us to investigate next the functional conse-
quences of this evolutionary turnover of IFIT1/ IFIT1B paralogs in mammals.
Discriminating IFIT1 and IFIT1B molecular functions using a novel
budding yeast assay
The ancient duplication and retention of IFIT1 and IFIT1B in most mammalian lineages suggested
that they have non-redundant functions. Based on our phylogenetic findings, in addition to previous
data suggesting human IFIT1 and mouse IFIT1B inhibit different viruses (Andrejeva et al., 2013;
Daffis et al., 2010; Pichlmair et al., 2011; Pinto et al., 2015), we hypothesized that IFIT1 and
IFIT1B might have evolved an alternative means of differentiating ’self versus non-self’ and distinct
antiviral specificities. We, therefore, investigated whether IFIT1 and IFIT1B proteins have distinct
molecular discrimination properties.
Previous characterizations of mouse IFIT1B clearly established its role in recognizing the methyla-
tion status of 5’ cap structure of mRNAs as a way to distinguish ’self’, or host, mRNAs from ’non-
self’, or viral, mRNAs (Daffis et al., 2010; Diamond, 2014; Fensterl and Sen, 2015; Hyde and Dia-
mond, 2015) (Figure 4A). However, most previous studies investigating mRNA cap requirements
for IFIT1B-mediated growth inhibition have been carried out in the context of a virus infection under
interferon-induced conditions. These approaches to understanding the function of individual IFIT
Figure 3 continued
Figure supplement 1. Phylogeny of vertebrate IFIT genes.
DOI: 10.7554/eLife.14228.010
Figure supplement 2. Recurrent gene conversion is restricted to the 5’ ends of IFIT genes.
DOI: 10.7554/eLife.14228.011
Figure supplement 3. Primate IFIT1 and IFIT1B genes.
DOI: 10.7554/eLife.14228.012
Figure supplement 4. Pseudogenization of IFIT1B genes from several primate lineages.
DOI: 10.7554/eLife.14228.013
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proteins are potentially complicated by the induction of hundreds of other ISGs, as well as the fact
several IFIT paralogs have been reported to bind to each other and function in a heterooligomeric
complex (Habjan et al., 2013; Pichlmair et al., 2011).
We, therefore, wished to assay the specificity of IFIT1 and IFIT1B molecular discrimination in an
orthogonal system. To this end, we turned to the budding yeast Saccharomyces cerevisiae, whose
mRNAs only have cap0-structures (Banerjee, 1980) due to a lack of a cap1-methyltransferase. Based
on this absence of a cap1-methyltransferase, we hypothesized that expression of mouse IFIT1B in
Figure 4. A yeast genetic assay recapitulates IFIT1B molecular specificity. (A) Schematic of mRNA cap structures
and the proposed role of mouse IFIT1B in recognition and inhibition of mRNAs containing cap0-structures.
Methylation of the first transcribed nucleotide of mRNAs, represented by an ’N’, is performed by cap1-
methyltransferases, such as human CMTR1 (hCMTR1). However, cap1-methyltransferase activity is absent in
budding yeast. Mouse IFIT1B binds and inhibits translation of cap0-mRNAs, but its activity is blocked when
mRNAs contain a cap1-structure. (B) A budding yeast growth assay for IFIT1B function. Since budding yeast lack a
cap1-methyltransferase, their mRNAs are predicted to be targeted by mouse IFIT1B. Shown are 10-fold serial
dilutions of yeast spotted on media in which the indicated IFIT is either not expressed (Glucose) or expressed
(Galactose). Rows marked with ’-’ indicate an empty vector control. (C) Predicted role for hCMTR1 in blocking
IFIT1B-mediated growth inhibition. (D–E) Yeast growth inhibition assays as in part B, but with galactose-induced
co-expression of the indicated methyltransferase (cap1-methyltransferase (hCMTR1) wildtype or catalytic mutant
(K239A)). In these panels, both IFIT and hCMTR1 expression are only induced upon grown on galactose-containing
media. Protein expression data corresponding to these yeast strains grown in galactose are shown in Figure 4—
figure supplement 1.
DOI: 10.7554/eLife.14228.014
The following figure supplement is available for figure 4:
Figure supplement 1. Expression of IFIT1B and cap1-methyltransferase proteins in yeast.
DOI: 10.7554/eLife.14228.015
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budding yeast might inhibit yeast growth just as IFIT1B inhibits replication of viruses with cap0-
mRNAs. Indeed, using a galactose-induced IFIT1B expression system, we found that expression of
mouse IFIT1B potently inhibits yeast growth (Figure 4B). Importantly, this growth inhibition occurs in
the absence of any other IFIT or component of the innate immune system, indicating that mouse
IFIT1B does not require any other mammalian-specific cofactor to perform this function. We next
hypothesized that introducing the human cap1-methyltransferase hCRMT1 to yeast would rescue
yeast growth by blocking the activity of IFIT1B (Figure 4C). Strikingly, we observed nearly complete
rescue of yeast growth when we co-expressed the human cap1-methyltransferase (hCMTR1), but not
Figure 5. IFIT1-mediated growth inhibition is not relieved by a cap1-methyltransferase. (A–C) Yeast growth
inhibition assays as in Figure 4 with the indicated IFIT1. (D) In contrast to IFIT1B, IFIT1 inhibits yeast growth
regardless of whether cap1-methyltransferase is present. (E) Pairwise comparison of the amino acid sequence of
cat IFIT1 and IFIT1B, with black vertical lines indicating differences between the two protein sequences. Shown
below are the pairwise amino acid identities for the N- and C-terminal regions of the alignment. (F) Yeast growth
inhibition assays as in Figure 4 with cat IFIT1 or IFIT1B. In these panels, both IFIT and hCMTR1 expression are only
induced upon grown on galactose-containing media. Protein expression data corresponding to these yeast strains
grown in galactose are shown in Figure 5—figure supplement 1.
DOI: 10.7554/eLife.14228.016
The following figure supplement is available for figure 5:
Figure supplement 1. Expression of IFIT1 proteins in yeast.
DOI: 10.7554/eLife.14228.017
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a catalytic mutant of hCMTR1 (K239A) (Belanger et al., 2010) (Figure 4D). We, therefore, conclude
that the mouse IFIT1B-mediated growth inhibition of budding yeast is specifically due to the lack of
a functional cap1-methyltransferase in yeast, accurately recapitulating the known antiviral molecular
specificity of IFIT1B (Figure 4C).
Based on our phylogenetic predictions, we next investigated whether other members of the
IFIT1B gene family have similar properties as the well-characterized mouse IFIT1B. If so, we pre-
dicted that they would also cause growth inhibition of yeast, but be rescued by overexpression of
the human cap1-methyltransferase. To test this hypothesis, we expressed IFIT1B from several pri-
mate species with or without co-expression of hCMTR1 (Figure 4E). Consistent with our phyloge-
netic prediction, we observed robust growth inhibition as a result of expression of gibbon and
African green monkey (AGM) IFIT1B that could be rescued by expression of hCMTR1. Thus, despite
the long divergence separating mouse and primate IFIT1B genes, they share molecular discrimina-
tion properties. Surprisingly, we observed no growth inhibition by human IFIT1B. This lack of activity
even upon equivalent expression in yeast (Figure 4—figure supplement 1) is unusual among intact
primate IFIT1Bs, suggesting that human IFIT1B lacks function. This result is consistent with previous
suggestions (Fensterl and Sen, 2011) that human IFIT1B may be non-functional even though it
appears to be encoded by an intact open reading frame.
We next tested our hypothesis that IFIT1 has evolved a distinct molecular function from that of
IFIT1B. Similar to mouse IFIT1B, we found that expression of human IFIT1 resulted in a potent inhibi-
tion of yeast growth (Figure 5A). However, in contrast to mouse IFIT1B, we observed no rescue of
human IFIT1-mediated growth inhibition upon overexpression of hCMTR1 (Figure 5B). IFIT1 proteins
from gibbon and African Green Monkey (AGM) recapitulate the findings from human IFIT1
(Figure 5C). These data indicate that IFIT1 proteins do not distinguish between absence or presence
of a cap1-methyltransferase (Figure 5D) but instead, likely recognize another as-yet-undefined ’non-
self’ molecular pattern, other than Cap0-mRNA, which is present in yeast.
These yeast genetic data indicate that human IFIT1 and mouse IFIT1B have evolved distinct
molecular functions. As described above, resolution of IFIT1 and IFIT1B genes into distinct monophy-
letic clades required considering only the non-recombining 3’ end of the genes (Figure 2). We,
therefore, asked whether differences in the C-terminal end of the IFIT1 and IFIT1B were responsible
for changes in their molecular specificity, as suggested by our phylogenetic analyses. Our initial chi-
meras between mouse IFIT1B and human IFIT1, or gibbon IFIT1 and IFIT1B, were unable to recapitu-
late the yeast growth inhibition. However, this result may be expected, as each of these proteins has
diverged without gene conversion for >30 million years and may have acquired epistatic interactions
between the N-terminus and the C-terminus.
As an alternate strategy to test whether the C-terminus is responsible for differences between
IFIT1 and IFIT1B function, we turned to a natural pair of IFIT1/IFIT1B proteins in which the N-termini
had recently undergone gene conversion. Cat IFIT1 and IFIT1B are 96% identical at the amino acid
level in the N-terminus of the protein whereas the C-terminus is only 46% identical (Figure 5E).
Upon overexpression in yeast, both cat IFIT1 and IFIT1B were capable of causing growth inhibition
(Figure 5F). However, only inhibition by cat IFIT1B was rescued by hCMTR1, suggesting that the C-
terminus of the IFIT1 paralogs is critical for the differences in the molecular specificity of these two
proteins. We, therefore, conclude that IFIT1 and IFIT1B gene families perform distinct molecular
functions in the species in which they are found and that recurrent gene conversion of the N-termini
of IFIT1/IFIT1B genes in mammals has not led to a loss of their separate functions.
IFIT1 and IFIT1B encode distinct antiviral specificities
We showed that IFIT1 and IFIT1B proteins are phylogenetically distinct and are functionally distinct
in their dependence on cap1-methyltransferase in our yeast assay. Next, we hypothesized that they
have non-overlapping antiviral activities. To test this hypothesis, we created cell lines that constitu-
tively overexpress different IFIT1 or IFIT1B genes (Figure 6A), circumventing the need to stimulate
IFIT expression with interferon and allowing us to evaluate different IFIT1 or IFIT1B gene functions in
an isogenic background. We then tested whether either human IFIT1 or mouse IFIT1B can specifi-
cally inhibit replication of a virus lacking a functional cap1-methyltransferase. For these experiments,
we compared replication of a wildtype (cap1-mRNA expressing) vaccinia virus to replication of a vac-
cinia virus that has a catalytic mutation in its cap1-methyltransferase (Latner et al., 2002). This assay
allowed us to test whether cap1-methyltransferase could enable a virus to block IFIT-mediated
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Figure 6. IFIT1B, but not IFIT1, inhibits replication of a cap0-containing virus. (A) Cell lines were generated that
express human IFIT1 or mouse IFIT1B, as assessed by western blot. (B) Predicted role for vaccinia virus cap1-
methyltransferase (J3) in blocking IFIT1B-mediated viral inhibition. (C) Cell lines expressing the indicated IFIT
protein were infected with either wildtype (left) or cap1-methlytransferase mutant (J3 K175A, right) vaccinia virus at
an MOI of 0.01. Virus was harvested at the indicated time point and titered. Error bars represent standard
deviation of three biological replicates. (D) As in panel C, but only showing data 24 hr post-infection with wildtype
(left) or the cap1-methyltransferase mutant (right) vaccinia virus. Shown below are protein expression levels from
uninfected cell lines.
DOI: 10.7554/eLife.14228.018
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antiviral activity (Figure 6B). Consistent with previous studies with these same viruses (Daffis et al.,
2010), we found that expression of mouse IFIT1B can potently inhibit replication of a mutant vaccinia
virus that lacks cap1-methyltransferase activity, but was unable to inhibit replication of wildtype vac-
cinia virus (Figure 6C). While the previous mouse knockout experiment had demonstrated that
mouse IFIT1B is necessary for inhibition of viruses encoding cap0-mRNAs (Daffis et al., 2010), our
findings show that singular overexpression of mouse IFIT1B is also sufficient for such inhibition. We
next extended our analyses to other members of the IFIT1 and IFIT1B gene families to determine if
cap0-mRNA dependence was a conserved feature of their antiviral activity. Consistent with our yeast
assay data, we found that gibbon and AGM IFIT1B proteins function similarly to mouse IFIT1B, and
can specifically inhibit the replication of a virus expressing cap0-mRNAs (Figure 6D). Also consistent
with our analyses of IFIT1B in yeast (Figure 4E), human IFIT1B lacks antiviral activity despite being
expressed in these cell lines. These results suggest that most IFIT1B proteins (except for the puta-
tively non-functional human IFIT1B) share cap0-mRNA recognition as a discriminant of their antiviral
function.
Figure 7. IFIT1, but not IFIT1B, inhibits replication of VSV, a cap1-containing virus. (A) Cell lines were infected with
vesicular stomatitis virus (VSV) encoding a GFP protein at an MOI of 0.01. After 12 hr, cells were visualized for
expression of the virally-encoded GFP. (B) Infections were performed as in part A, but at the indicated timepoint,
virus was harvested and titered. Error bars represent standard deviation of three biological replicates. (C)
Infections were performed as in part A, harvested after 12 hr, and titered. Error bars represent standard deviation
of three biological replicates. (D) In contrast to IFIT1B, IFIT1 inhibits VSV growth arrest regardless of the fact that
cap1-methyltransferase is present.
DOI: 10.7554/eLife.14228.019
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In contrast to the activity of most IFIT1B proteins, human IFIT1 did not inhibit replication of the
vaccinia virus methyltransferase mutant (Figure 6C). Consistent with our yeast data, these results
demonstrated that human IFIT1 does not discriminate ’self versus non-self’ based on cap0-mRNA
versus cap1-mRNA specificity. Likewise, neither gibbon nor AGM IFIT1 was able to inhibit the cap0-
mRNA expressing vaccinia virus (Figure 6D). We, therefore, conclude that in keeping with their phy-
logenetic divergence, IFIT1B and IFIT1 lineages evolved to rely on distinct cues for their function.
Such non-redundancy could explain the retention of both IFIT1 and IFIT1B in most mammalian
genomes.
These results also suggest that there likely exist viruses that are specifically inhibited by IFIT1 but
not IFIT1B. To identify such viruses, we took advantage of previous studies, which showed that
knockdown of human IFIT1 can augment replication of several viruses expressing a functional cap1-
methyltransferase (Andrejeva et al., 2013; Pichlmair et al., 2011). Based on our findings and others
(Daffis et al., 2010; Hyde et al., 2014; Ma et al., 2014; Menachery et al., 2014; Szretter et al.,
2012; Zust et al., 2011; Habjan et al., 2013; Kimura et al., 2013; Kumar et al., 2014) we expect
that all cap1-mRNA expressing viruses would be resistant to IFIT1B restriction. We, therefore,
infected our cell lines expressing either human IFIT1 or mouse IFIT1B with vesicular stomatitis virus
(VSV), a virus known to express mRNAs with a cap1-structure (Ma et al., 2014; Banerjee, 1980). As
expected, we found that mouse IFIT1B had no effect on either virally-encoded GFP expression
(Figure 7A) or viral titers (Figure 7B). VSV viral titers were also unaffected by other IFIT1B genes
(Figure 7C). In contrast, we observed a substantial decrease in both viral-GFP expression and viral
titer in cells expressing human IFIT1 (Figure 7A,B). This inhibitory activity was also conserved in
other primate IFIT1 proteins (Figure 7C), suggesting that multiple IFIT1 proteins are insensitive to
cap1-methyltransferase and share the property of inhibiting VSV (Figure 7D). Together with our vac-
cinia virus data (Figure 6), these data support the conclusion that IFIT1B and IFIT1 encode non-
redundant antiviral specificities that together expand the antiviral range of the IFIT gene repertoire
in mammals.
Discussion
Rapid gene evolution is a hallmark of antiviral proteins. Immunity proteins are driven to innovate
continually to maintain effective defenses against an evolving barrage of pathogens (Daugherty and
Malik, 2012). One common genetic mechanism of innovation employed by host genomes is gene
duplication, which enables hosts to either escape viral antagonism or evolve new inhibitory mecha-
nisms through subfunctionalization. Indeed, many antiviral genes expressed as part of the interferon
response represent members of multigene families, whose lineage-specific expansions and contrac-
tions have shaped contemporary repertoires of antivirals in mammalian genomes (Brunette et al.,
2012; Daugherty and Malik, 2012; Munk et al., 2012; Tareen et al., 2009; Zhang et al., 2012). In
several of these multigene families, gene conversion has further diversified the innate immune reper-
toire of different species (Buchmann, 2014; Mitchell et al., 2015; Woelk et al., 2007).
Despite being among the most highly expressed interferon-stimulated genes (ISGs), the function
of the IFIT antiviral genes is still incompletely understood. Previously, several IFITs, including mouse
IFIT1B (previously IFIT1) and human IFIT1, were shown to inhibit protein synthesis (Guo et al., 2000;
Hui et al., 2003; Terenzi et al., 2005). These findings are consistent with mRNA translation control
being a major axis of regulation of viral replication (Mohr and Sonenberg, 2012; Li et al., 2015).
Furthermore, the finding that mouse IFIT1B represses the translation of mRNAs lacking Cap1-struc-
tures appeared to resolve the conundrum of how at least this IFIT protein discriminates between
’self’ and ’non-self’ (Daffis et al., 2010). However, the broad application of this result for IFIT1 func-
tion was complicated by apparently contradictory findings that mouse and human representatives of
IFIT1 have different antiviral specificities (Andrejeva et al., 2013; Daffis et al., 2010;
Pichlmair et al., 2011; Pinto et al., 2015). Thus, it remained unclear how different IFIT proteins rec-
ognize and inhibit replication of different viruses, and whether and how the changes in IFIT gene
composition between species (e.g. humans and mice) have altered their antiviral repertoire.
To provide an evolutionary framework for understanding how the IFIT antiviral repertoire evolved
in mammals, we performed in-depth phylogenetic analyses. We find unambiguous evidence that,
although they were initially assumed to be orthologs, mouse IFIT1B (previously mouse IFIT1) and
human IFIT1 represent paralogous genes that diverged close to the origin of placental mammals.
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We further showed that the IFIT gene family, especially IFIT1 and IFIT1B genes, have undergone
recurrent bouts of gene duplication, gene loss, and gene conversion. These processes have resulted
in a wide diversity of IFIT genes across mammalian species. Such changes in IFIT gene composition
might be expected to affect the range of viruses that can be inhibited by IFITs in different mamma-
lian genomes.
Based on their long divergence, we predicted that mouse (and other) IFT1B and human (and
other) IFIT1 protein might possess different antiviral specificities. Consistent with this prediction, our
data indicate that only IFIT1B proteins distinguish ’self from non-self’ mRNAs by recognizing an
unmethylated (cap0-) mRNA structure, a molecular pattern that is absent on 2’O-methylated (cap1-)
host mRNAs. However, the general antiviral effectiveness of IFIT1B proteins is limited due to the fact
that every mammalian virus family, except alphaviruses, has evolved a way to produce cap1-mRNAs.
Viral cap1-mRNAs are produced either by nuclear transcription and use of the host nuclear capping
machinery (e.g., retroviruses and many DNA viruses), or cap-snatching (e.g., orthomyxoviruses), or
virally encoding cap1-methyltransferases (e.g., poxviruses and rhabdoviruses) (Banerjee, 1980;
Decroly et al., 2012; Hyde and Diamond, 2015). Even in the case of alphaviruses, which produce
cap0-mRNAs (Banerjee, 1980) and are therefore predicted to be susceptible to IFIT1B-mediated
inhibition, secondary structure changes at the 5’ end of alphaviral mRNAs can blunt IFIT1B antiviral
action (Hyde et al., 2014). Given all of these viral counter-strategies, it might appear that IFIT1B is
on the losing side of the arms race between host and most viruses. These counter-strategies may
partially explain why we find that IFIT1B has been deleted or pseudogenized at least seven separate
times in mammalian evolution. Even in humans, which encode a full-length IFIT1B ORF, IFIT1B activ-
ity appears to have been lost both due to lack of interferon-inducibility (Fensterl and Sen, 2011) as
well as loss of protein function (Figure 4E and 6D).
Humans and most other mammalian species (excluding rodents) do, however, have an intact
member of the IFIT1 gene family. IFIT1 mechanism and antiviral specificity have been enigmatic in
part due to incorrect comparisons with mouse IFIT1B. By experimentally separating the functions of
IFIT1 and IFIT1B from the rest of the innate immune system, we now show that IFIT1 has evolved a
molecular specificity that differs from IFIT1B and is not blocked by cap1-methyltransferase. For
example, using a yeast genetic assay, we show that IFIT1, unlike IFIT1B, potently inhibits yeast
growth independent of whether human cap1-methyltransferase is co-expressed. Moreover, IFIT1,
but not IFIT1B, inhibits replication of VSV, a virus encoding a cap1-methyltransferase. These results
establish that these two paralogous immunity factors have distinct molecular function and highlight
a significant role for IFIT1 in specific antiviral defense that is distinct from IFIT1B.
Our study does not elucidate the molecular means by which human IFIT1 inhibits viral replication.
While several possibilities exist for how IFIT1-mediated translational repression might be controlled,
we favor the possibility that IFIT1, like its paralog IFIT1B, distinguishes a ’self versus non-self’ pattern
on mRNA to selectively inhibit viral replication. Supporting this model is the fact that in addition to
IFIT1B, IFIT2 and IFIT5 have been reported to have sequence- or structure-specific binding to RNA
(Habjan et al., 2013; Katibah et al., 2013; 2014; Yang et al., 2012), suggesting that numerous
IFITs may restrict viral replication through recognition of distinct viral RNA patterns. Although the
presumed molecular pattern that IFIT1 recognizes remains unknown, our data suggest that mamma-
lian hosts, as well as vaccinia virus, possess a ’self’ molecular pattern to prevent IFIT1-mediated inhi-
bition whereas yeast and VSV display a ’non-self’ molecular pattern that cannot block IFIT1 action.
One previous proposal suggested that human IFIT1 antiviral activity resulted from direct binding and
sequestration of 5’ triphosphate ends of viral replication intermediates, thus interfering with replica-
tion rather than directly inhibiting translation (Pichlmair et al., 2011). We instead favor a model in
which IFIT1 recognizes a distinct ’self versus non-self’ pattern to inhibit mRNA translation directly,
similar to IFIT1B. Biochemical data suggests that IFIT1, like IFIT1B, binds to cap-proximal RNA and
prevents binding of mRNAs by the translation initiation factor eIF4F (Kumar et al., 2014). Moreover,
human IFIT1 was shown to not just inhibit replication of PIV5, but to inhibit translation of PIV5 2’O-
methylated mRNAs (Andrejeva et al., 2013). Finally, our observation that IFIT1 expression also
inhibits yeast growth suggests that it is not a viral replication intermediate, but rather a ’non-self’
pattern, which is recognized by IFIT1, similar to the lack of mRNA 2’O-methylation for IFIT1B. While
the methylation state of the first transcribed nucleotide (cap0-structure versus cap1-structure) is not
the determinant of IFIT1 specificity, other chemical modifications near the cap, or mRNA sequence
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determinants, may allow IFIT1 to distinguish ’self’ from ’non-self’ to selectivity inhibit viral
replication.
Although gene conversion and gene turnover initially confounded IFIT phylogenetic analysis, it
may now present a significant opportunity to understand the biochemical basis of the different anti-
viral specificities of IFIT1 and IFIT1B. For instance, two cat IFIT proteins, which are practically identi-
cal in their N-terminal two-thirds, but divergent in their C-terminus, fully recapitulate the expected
properties of IFIT1 and IFIT1B in our yeast assay. Use of other such ‘natural’ chimeras can help guide
the biochemical dissection of what provides IFIT1B with its unique cap0-mRNA recognition proper-
ties and provide insight into how IFIT1 has evolved its distinct specificity. The naturally occurring
recombination breakpoint in the IFIT1/1B gene conversion tracts also suggests features of IFITs that
are critical for a common aspect of IFIT1/1B activity versus those that promote their distinct molecu-
lar specificity. In the structures of IFIT5 bound to the 5’ triphosphate containing end of RNA, three
’subdomains’ surround the RNA (Abbas et al., 2013). The recombination breakpoint we observed
falls within the ’pivot’ region separating the second and third subdomain (Figure 2—figure supple-
ment 2), suggesting the first two subdomains may be important for a common conserved function
of IFIT1 and IFIT1B whereas the third subdomain might confer changes to the molecular specificity.
We also note that the breakpoint occurs just outside of the homooligomerization domain in the
structure of IFIT2 (Yang et al., 2012). As some IFITs are thought to oligomerize for function
(Habjan et al., 2013; Pichlmair et al., 2011), the homogenization of the region corresponding to
the oligomerization domain in IFIT2 suggests that IFIT1 and IFIT1B might also need to hetero-oligo-
merize in species in which both are present.
Based on our new understanding of the divergent functions of IFIT1 and IFIT1B, we hypothesize
that duplication or loss of different IFIT genes might directly influence the ability of a particular host
species to defend against specific viral pathogens. For instance, the duplication of IFIT1B genes in
rodents might have been driven by pressure from alphaviruses or other undiscovered cap0-mRNA
expressing viruses, and may augment the defenses of rodent hosts against such viruses. In contrast,
the loss of IFIT1 in many rodents might leave them more susceptible to infection by viruses inhibited
by IFIT1, such as VSV. Similarly, loss of IFIT1B function in a broad range of species, including humans,
may result in greater ability of cap0-mRNA expressing viruses to replicate in those species. In that
regard, rodents may be better prepared than humans, chimpanzees, New World monkeys and sev-
eral other species to defend against cap0-mRNA expressing viruses such as alphaviruses (Figure 3).
Thus, IFIT gene duplication may be the host’s response to the evolutionary arms race where viruses
are continually masking their RNAs with ’self’ features. On the other hand, when the selective pres-
sure from viruses displaying a given ’non-self’ feature (e.g. Cap0-mRNAs) has been relaxed, the spe-
cific IFIT gene that restricts those viruses may be pseudogenized or lost permanently. Although
compensatory mechanisms may have evolved that mitigate the consequences of loss of a single IFIT,
our results indicate that lineage-specific loss of IFIT genes eliminates an elegant means to discrimi-
nate ‘self versus non-self’ RNAs from the host’s armament. We predict that the dynamic evolution of
IFIT genes across mammals will have important consequences for species-specific antiviral immunity.
Materials and methods
Phylogenetic analyses
Mammalian IFIT genes were identified in genomes of the indicated species using human IFIT protein
sequences to query the non-redundant (nr) database using tBLASTn (Altschul et al., 1997) (see
Supplementary file 1 for accession numbers). In human IFIT genes, the entire protein-encoding
sequence except for the N-terminal methionine is encoded on a single exon. For the species indi-
cated in Figure 1, we used this information to include only IFIT sequences that were found on a sin-
gle uninterrupted region of DNA in either NCBI or UCSC genome databases. For the broader panel
of species shown in Figures 2 and 3, several of the genomes are not as well assembled and we
therefore did not eliminate genes based on these criteria but insisted that >90% of the gene
sequence be available in NCBI. IFIT sequences were aligned based on their translated sequence
using MUSCLE (Edgar, 2004) implemented in Geneious (Kearse et al., 2012). All alignments were
manually curated using Geneious (Kearse et al., 2012). Maximum likelihood phylogenetic trees of
IFIT nucleotide sequences were generated using the HKY85 substitution model in PhyML
Daugherty et al. eLife 2016;5:e14228. DOI: 10.7554/eLife.14228 17 of 22
Research Article Genomics and evolutionary biology Microbiology and infectious disease
(Guindon et al., 2010) using 1000 bootstrap replicates for statistical support. K-estimator
(Comeron, 1999) was to calculate the rate of synonymous change (dS) for each 200 nt window of
pairwise comparisons of IFIT1 and IFIT1B genes. To examine the alignments for evidence of recom-
bination breakpoints, we used the SBP and GARD algorithms implemented at DataMonkey.org
(Kosakovsky Pond et al., 2006). Pairwise percent identity calculations and graphical representations
were made using Geneious (Kearse et al., 2012). Phylogenetic trees were visualized using FigTree
(http://tree.bio.ed.ac.uk/software/figtree/). Protein structural figures were generated using PyMol
(https://www.pymol.org).
Construction of yeast strains
Previous studies have utilized budding yeast as a genetic assay system for PKR-mediated mRNA
translation inhibition by showing that PKR expression in yeast arrests growth (Dever et al., 1993).
We therefore asked whether expression of IFIT genes in yeast would also arrest growth. IFIT genes
with an N-terminal 3xFlag tag were cloned downstream of the Gal1-10 promoter in the Cen-based
plasmid, p413, using primers described in Supplementary file 2. Yeast (strain BY4741) were trans-
formed and selected on synthetic complete media lacking histidine and containing 2% glucose (SC -
his GLU). For expression of methyltransferases and IFITs, human methyltransferases were integrated
into strain BY4741 to replace the His3 gene and then transformed with p413 plasmids expressing
IFITs. First, the human genes for hCMTR1 or hCMTR1 K239A methyltransferases were cloned down-
stream of the Gal1-10 promoter of pRS305-Gal1 using primers described in Supplementary file 2.
The resulting plasmids were used as templates to amplify the entire region spanning the Gal pro-
moter to the Leu2 gene using primers described in Supplementary file 2 with 70 bp homology to
the genomic regions flanking the His3 gene. The resulting PCR products were transformed into
strain BY4741 and yeast were selected on media lacking leucine (SC -leu GLU). Yeast with integrated
galactose-inducible methyltransferases were subsequently transformed with IFIT genes as described
above and selected on media lacking both leucine and histidine (SC -leu/-his GLU).
Yeast growth assays
All yeast plating assays were performed on selective media with either 2% glucose (for uninduced
controls) or 2% galactose (for induction of IFIT and methyltransferase genes). A single yeast colony
was picked from a freshly streaked plate of transformed yeast and grown overnight at 30 degrees in
liquid media (SC -his GLU or SC -his/-leu GLU). Saturated overnight cultures were serially diluted 10-
fold from a starting OD600 of 1 and spotted onto selective plates containing glucose or galactose.
Plates were incubated at 30 degrees for 48–72 hr.
Construction of cell lines expressing IFITs
The retroviral packaging vector pQCXIP (Clontech, Mountain View, CA) was used as a backbone for
generation of all stable cell lines. First, an insert containing mCherry followed by a T2A site followed
by a 3xFlag tag was cloned downstream of the CMV promoter of pQCXIP, resulting in plasmid
pMD143 (see Supplementary file 2). All IFIT genes were inserted in frame with the 3xFlag tag of
pMD143 using primers and templates described in Supplementary file 2. The resulting plasmids
were used to generate VSV-g pseudotyped retroviruses that were then used to transduce BSC40
cells, an African green monkey derived kidney epithelial cell line. The BSC40 cells have been rou-
tinely screened for mycoplasma infections and validated as being of African Green monkey origin
using RT-PCR analyses. We also note that BSC40 cells are not on the list of commonly misidentified
cell lines maintained by the International Cell Line Authentication Committee. Stably transduced
BSC40 cells were selected and maintained in culture media (DMEM with 10% FBS) containing 10 ug/
ml puromycin. All cell lines were assayed within the first 20 passages following transduction.
Viral infectivity assays
Vaccinia virus strain WR wildtype or cap1-methyltransferase mutant (J3 K175R) were a generous gift
of R. Condit (Latner et al., 2002). VSV-GFP was a generous gift of J. Rose (Boritz et al., 1999). For
infectivity assays, BSC40 cells stably transduced with pMD143 containing various IFIT gene inserts
were seeded to 24-well plates ( ~50000 cells/well) and allowed to grow overnight. Cells were incu-
bated with vaccinia virus or VSV-GFP at a multiplicity of infection (MOI) of 0.01 for two hours,
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followed by a media change. Vaccinia virus was harvested at the indicated time post-infection by
freeze/thaw disruption of cells. VSV-GFP was harvested from cell supernatant at the indicated time
post-infection. Viruses were titered on BSC40 cells either with agar overlays (for VSV-GFP) or without
(for vaccinia virus). All infectivity data is reported as average of three biological replicates (indepen-
dent infections followed by titering) plus and minus the standard deviation.
Western blotting for protein expression
The following commercially available primary antibodies were used: mouse M2 anti-Flag (Sigma-
Aldrich, St. Louis, MO; F1804), rabbit anti-hCMTR1 (Sigma-Aldrich; HPA029979), mouse anti-PGK1
(Invitrogen, Carlsbad, CA; 459250), and rat anti-tubulin (Millipore, Temecula, CA; CBL270). Goat
anti-mouse, anti-rat and anti-rabbit HRP-conjugated secondary antibodies were from Santa Cruz
Biotechnology (Dallas, TX).
For analysis of protein expression from stably transduced BSC40 cells, ~ 200000 cells were har-
vested and lysed by boiling in 2x SDS sample buffer. For analysis of protein expression from yeast, a
single yeast colony was picked from a freshly streaked plate of transformed yeast and grown over-
night in liquid selective media containing 2% raffinose (SC -his/-leu RAF). Cultures were diluted in SC
-his/-leu RAF to 0.5 OD600 and grown 3 more hours at which point galactose was added to a final
concentration of 2%. After 90 min, cultures were spun down and frozen. Cell pellets were resus-
pended in 2x SDS sample buffer containing protease inhibitors and bead beaten for 30 s. All cell
lysates (yeast and mammalian) were run on 4–12% Bis-Tris gels (Invitrogen) and transferred onto
nitrocellulose membrane. Blocking buffer and antibody dilution buffer for hCMTR1 blots was 5%
bovine serum albumin in phosphate buffered saline (PBS) with 0.1% Tween-20. Blocking buffer and
antibody dilution buffer for all other blots was 5% nonfat dried milk in PBS with 0.1% Tween-20.
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